Brief: Alzecure Pharma Enters Into Collaboration, Out-Licensing Agreement With Lilly For Alzheimer’s Project
09/06/2026 06:12
BRIEF-Alzecure Pharma Enters Into Collaboration, Out-Licensing Agreement With Lilly For Alzheimer’s Project June 9 (Reuters) - AlzeCure Pharma AB ALZCUR.ST:
ENTERS INTO A COLLABORATION AND OUT-LICENSING AGREEMENT WITH LILLY FOR ALZHEIMER’S PROJECT
DEAL VALUE MAY EXCEED $1 BILLION EXCLUDING ROYALTIES; $10 MILLION UPFRONT PAYMENT TO ALZECURE
DEAL SUBJECT TO SWEDISH AUTHORITY APPROVAL UNDER FOREIGN DIRECT INVESTMENT REGULATIONS
Source text: ID:nMFN5pzQ2t
Further company coverage: ALZCUR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)